Chicago Growth Partners Leads Growth Buyout of Caprion Proteomics
(en anglais seulement...) CGP partners with the management team of the leading provider of integrated proteomic and immune monitoring services.
Chicago Growth Partners is excited to announce the recapitalization of Caprion Proteomics, Inc. Caprion is the leading provider of integrated proteomic biomarker and target identification solutions and advanced immune monitoring services to the world’s largest and most successful pharmaceutical and biotechnology companies as well as government research organizations.
Dr. Arda Minocherhomjee, Managing Partner of CGP commented, “Caprion is the best-in-class provider of integrated proteomic and advanced immune monitoring services. The Company is well positioned to gain share in these rapidly growing market segments as the use of biomarkers continues to grow in oncology and in other segments, and pharmaceutical and biotechnology companies continue to outsource more of their research and development work.”
Caprion’s key services include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) clinical diagnostic product development. The Company’s multi-disciplinary team which includes experts in biology, chemistry, and bioinformatics has developed a highly integrated, industrialized approach that produces unrivaled information used by pharmaceutical and biotechnology clients to manage their therapeutic development pipelines.
Martin LeBlanc, President and CEO of Caprion commented, “We are very pleased with this transaction and to
begin this exciting new partnership with Chicago Growth Partners. CGP’s solid track record of successfully supporting management teams and providing strategic leadership will help position Caprion to sustain the rapid growth achieved over the past four years as we continue to capitalize on the growing demand for integrated proteomic and advanced immune monitoring services in the development of novel therapeutics and diagnostics.”
Caprion’s proprietary CellCarta technology is the leading biomarker discovery and validation platform in the growing field of integrated proteomics, and has overcome technical limitations of earlier proteomics technologies by developing and effectively putting into industrial practice a powerful proteomics engine for highly multiplexed, unbiased measurement of protein abundance differences across large sample sets.
The Company’s proprietary ImmuneCarta technology develops and routinely provides cell-mediated 14-color flow cytometry assays in a good laboratory practices (“GLP”) environment which allows the data provided by these studies to be included in a client’s FDA submission as part of a clinical study. It enables detailed multi-parametric monitoring of antigen specific immune responses to therapeutic treatment (vaccines and immunotherapies), which
helps its pharmaceutical and biotechnology clients address immunology related development objectives at the discovery, pre-clinical, and clinical stages.
Over the past five years Caprion has identified and verified certain combinations of biomarkers that can be used to develop proteomic-based disease state and companion diagnostic products. Over the next three to five years CGP and management will work together to implement the optimal strategy to expand and further the development of the diagnostic product pipeline as well as begin the commercialization of these assets.
The CGP deal team included Dr. Arda Minocherhomjee, Rob Healy, Sean Barrette, and Jim Holms.
About Chicago Growth Partners
For over 25 years and across more than 100 growth companies, the principals of Chicago Growth Partners have
partnered with quality management teams to help facilitate their growth objectives. CGP executes its growth-focused investment strategy across four industries: Education, Healthcare, Tech-Enabled Services and Industrial Growth, where our expertise in information technology, marketing, and finance can often be helpful to our management teams. CGP currently manages $1.2 billion of committed capital and has offices in Chicago and La Jolla. For more information on Chicago Growth Partners, please visit www.cgp.com.